Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

F Hunter

Showing results (471-480 of 502) with videos related to

Pageof 51
Sort By:
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Frontiers in Psychology|November 19, 2025
Moderators of peer influence effects for adolescents' smoking and vaping norms and outcomes in high and middle-income settingsJennifer M Murray, Sharon C Sánchez-Franco, Olga L Sarmiento, et al.
Frontiers in Public Health|August 28, 2020
MECHANISMS Study: Using Game Theory to Assess the Effects of Social Norms and Social Networks on Adolescent Smoking in Schools-Study ProtocolRuth F Hunter, Felipe Montes, Jennifer M Murray, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Neurology and Therapy|May 16, 2020
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS StudiesAntonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, et al.
American Journal of Medical Genetics. Part A|November 9, 2022
Tissue mosaicism, FMR1 expression and intellectual functioning in males with fragile X syndromeEmma K Baker, Marta Arpone, Minh Bui, et al.
Scientific Reports|July 18, 2020
FMR1 mRNA from full mutation alleles is associated with ABC-C<sub>FX</sub> scores in males with fragile X syndromeEmma K Baker, Marta Arpone, Claudine Kraan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 9, 2023
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studiesColin M Dayan, Beatriz Lecumberri, Ilaria Muller, et al.
Scientific Reports|February 28, 2018
Intragenic DNA methylation in buccal epithelial cells and intellectual functioning in a paediatric cohort of males with fragile XMarta Arpone, Emma K Baker, Lesley Bretherton, et al.
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Pageof 51

Showing results (471-480 of 502) with videos related to

Sort By:
Pageof 51
Advances in Therapy|February 25, 2022
Efficacy and Safety Outcomes with Diroximel Fumarate After Switching from Prior Therapies or Continuing on DRF: Results from the Phase 3 EVOLVE-MS-1 StudySibyl Wray, Florian Then Bergh, Annette Wundes, et al.
Frontiers in Psychology|November 19, 2025
Moderators of peer influence effects for adolescents' smoking and vaping norms and outcomes in high and middle-income settingsJennifer M Murray, Sharon C Sánchez-Franco, Olga L Sarmiento, et al.
Frontiers in Public Health|August 28, 2020
MECHANISMS Study: Using Game Theory to Assess the Effects of Social Norms and Social Networks on Adolescent Smoking in Schools-Study ProtocolRuth F Hunter, Felipe Montes, Jennifer M Murray, et al.
Neurology and Therapy|June 24, 2021
Confirmed 6-Month Disability Improvement and Worsening Correlate with Long-term Disability Outcomes in Alemtuzumab-Treated Patients with Multiple Sclerosis: Post Hoc Analysis of the CARE-MS StudiesSamuel F Hunter, Rany A Aburashed, Raed Alroughani, et al.
Neurology and Therapy|May 16, 2020
Quality of Life Improves with Alemtuzumab Over 6 Years in Relapsing-Remitting Multiple Sclerosis Patients with or without Autoimmune Thyroid Adverse Events: Post Hoc Analysis of the CARE-MS StudiesAntonio Bertolotto, Rafael Arroyo, Elisabeth G Celius, et al.
American Journal of Medical Genetics. Part A|November 9, 2022
Tissue mosaicism, FMR1 expression and intellectual functioning in males with fragile X syndromeEmma K Baker, Marta Arpone, Minh Bui, et al.
Scientific Reports|July 18, 2020
FMR1 mRNA from full mutation alleles is associated with ABC-C<sub>FX</sub> scores in males with fragile X syndromeEmma K Baker, Marta Arpone, Claudine Kraan, et al.
Multiple Sclerosis Journal - Experimental, Translational and Clinical|January 9, 2023
Endocrine and multiple sclerosis outcomes in patients with autoimmune thyroid events in the alemtuzumab CARE-MS studiesColin M Dayan, Beatriz Lecumberri, Ilaria Muller, et al.
Scientific Reports|February 28, 2018
Intragenic DNA methylation in buccal epithelial cells and intellectual functioning in a paediatric cohort of males with fragile XMarta Arpone, Emma K Baker, Lesley Bretherton, et al.
CNS Drugs|July 26, 2020
Efficacy and Safety of Alemtuzumab Through 9 Years of Follow-up in Patients with Highly Active Disease: Post Hoc Analysis of CARE-MS I and II Patients in the TOPAZ Extension StudyTjalf Ziemssen, Ann D Bass, Regina Berkovich, et al.
Pageof 51